These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31930323)

  • 21. Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor: A case report.
    Oe Y; Kameda H; Nomoto H; Sakamoto K; Soyama T; Cho KY; Nakamura A; Iwasaki K; Abo D; Kudo K; Miyoshi H; Atsumi T
    Medicine (Baltimore); 2021 Nov; 100(46):e27895. PubMed ID: 34797338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Refractory hypophosphatemia following ferric carboxymaltose administration.
    Efe O; García JDC; Mount DB; Sheridan AM
    CEN Case Rep; 2021 Nov; 10(4):473-475. PubMed ID: 33715107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.
    Toi N; Imanishi Y; Nagata Y; Kurajoh M; Morioka T; Shoji T; Shinto Y; Emoto M
    Endocr J; 2023 Apr; 70(4):419-426. PubMed ID: 36575021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iatrogenic osteomalacia: report of two cases.
    Yamamoto S; Okada Y; Mori H; Kurozumi A; Torimoto K; Arao T; Tanaka Y
    J UOEH; 2013 Mar; 35(1):25-31. PubMed ID: 23475021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Bone and Nutrition. The relationship between iron and phosphate metabolism].
    Takashi Y; Fukumoto S
    Clin Calcium; 2015 Jul; 25(7):1037-42. PubMed ID: 26119317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome.
    Sugarman J; Maruri A; Hamilton DJ; Tabatabai L; Luca D; Cimms T; Krolczyk S; Roberts MS; Carpenter TO
    Bone; 2023 Jan; 166():116598. PubMed ID: 36341949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
    Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
    BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood and Bone Loser.
    Schaefer B; Glodny B; Zoller H
    Gastroenterology; 2017 May; 152(6):e5-e6. PubMed ID: 28384445
    [No Abstract]   [Full Text] [Related]  

  • 29. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.
    Edmonston D; Wolf M
    Nat Rev Nephrol; 2020 Jan; 16(1):7-19. PubMed ID: 31519999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial.
    Adkinson NF; Strauss WE; Macdougall IC; Bernard KE; Auerbach M; Kaper RF; Chertow GM; Krop JS
    Am J Hematol; 2018 May; 93(5):683-690. PubMed ID: 29417614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron supplementation in a case of severe iron deficiency anaemia.
    Füllenbach C; Triphaus C; Glaser P; Ziebart A; Zacharowski K; Meybohm P; Choorapoikayil S
    Br J Anaesth; 2018 Aug; 121(2):502-504. PubMed ID: 30032895
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term use of burosumab for the treatment of tumor-induced osteomalacia.
    Crotti C; Zucchi F; Alfieri C; Caporali R; Varenna M
    Osteoporos Int; 2023 Jan; 34(1):201-206. PubMed ID: 35925260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.
    Schaefer B; Zoller H; Wolf M
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1009-1019. PubMed ID: 34850000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.
    Schouten BJ; Hunt PJ; Livesey JH; Frampton CM; Soule SG
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2332-7. PubMed ID: 19366850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parenteral iron therapy and phosphorus homeostasis: A review.
    Kalantar-Zadeh K; Ganz T; Trumbo H; Seid MH; Goodnough LT; Levine MA
    Am J Hematol; 2021 May; 96(5):606-616. PubMed ID: 33471363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron Infusion and Induced Hypophosphatemia: The Role of Fibroblast Growth Factor-23.
    Coppolino G; Nicotera R; Cernaro V; Calimeri S; Leonardi G; Cosentino S; Comi A; Donato C; Lucia CM; Provenzano M; Michael A; Andreucci M
    Ther Apher Dial; 2020 Jun; 24(3):258-264. PubMed ID: 31483921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
    Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T
    Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Burosumab: Current status and future prospects.
    Goyal A; Tandon N
    Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101826. PubMed ID: 37858479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.